Overview: NGS Duchenne Becker MD Sequencing TestIntroduction: The NGS Duchenne Becker MD Sequencing Test sequences genes for MLPA-negative cases to diagnose muscular dystrophy, causing muscle weakness. Following 2023 MDA guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected Duchenne or Becker muscular dystrophy (DMD/BMD) after negative MLPA results.
Other Names: DMD/BMD Assay, Dystrophin Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: DMD/BMD sequencing began in the 1980s with dystrophin gene discovery. NGS methods improved in the 2010s, enhancing diagnostic precision for MLPA-negative cases.
Purpose: Sequences genes to diagnose DMD/BMD in MLPA-negative cases, guides treatment, and evaluates patients with muscle weakness.
Test Parameters: 1. DMD/BMD Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of muscle weakness, delayed motor milestones, or DMD/BMD symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document muscle weakness, calf hypertrophy, Gowers sign, or family history of DMD/BMD. Include current medications, especially corticosteroids.
Consent: Written consent required, detailing the tests purpose, DMD/BMD implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze DMD/BMD genes (e.g., dystrophin gene) in MLPA-negative cases. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for DMD/BMD diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm DMD/BMD, guiding corticosteroid therapy, exon-skipping drugs, or genetic counseling. Negative results may require muscle biopsy.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Muscle biopsy, creatine kinase levels, or EMG to confirm DMD/BMD diagnosis.
Test Limitations: Not all DMD/BMD cases are detected in MLPA-negative samples; clinical correlation is needed. Sample quality affects sensitivity.
References: MDA Muscular Dystrophy Guidelines, 2023; Neurology, Darras BT, 2022.
